Twist Bioscience.
Biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 58
What's happening
Earlier this month
-
Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Some support6 reports
-
VUG concentrates on large-cap leaders like Nvidia. VUG holds large-cap leaders such as Microsoft. VUG holds established giants including Apple. IWO holds small-cap equities including Twist Bioscience.Some support1 report
One to three months ago
-
Twist Bioscience and BioLife Solutions are healthcare companies in the biotech sector listed on Nasdaq.Some support1 report
-
Corcept Therapeutics and Twist Bioscience are noted as holdings within the First Trust biotech fund.Some support1 report
-
Sean McClain discusses the AI/biotech space, noting that Anthropic and Twist Bioscience operate in this sector.Some support1 report
-
Twist Bioscience underperformed the market so far this year, based on data from August 4, 2025.Some support2 reports
-
Paula Green sold shares of Twist Bioscience stock, and Millennium Management increased its holdings in the company on July 29, 2026.Some support2 reports
Gone quiet
No new reports in 90+ days-
ISI (Twist Bioscience) was listed on the Nasdaq stock exchange, and Barclays raised its price target on the company on July 9, 2026.Some support3 reports
-
Thermo Fisher Scientific and Twist Bioscience benefit from Trump-era tariffs while operating in the life sciences sector.Some support1 report
-
Twist Bioscience filed disclosures with the SEC, listed its stock on Nasdaq, and received a rating upgrade from TD Cowen.Some support2 reports
-
Insider sold shares of Twist Bioscience stock on June 24, 2026.Some support1 report
-
Life sciences companies Danaher Corporation and Twist Bioscience are facing headwinds due to exposure to China and academic spending.Some support1 report
-
Twist Bioscience announced an accelerated Express turnaround time for all gene fragments.Speculative1 report
-
Twist Bioscience and LinkedIn were involved in an event on July 24, 2025.Some support1 report
-
Conestoga Capital Advisors highlighted Twist Bioscience in its investor letter on July 28, 2025.Some support1 report
-
Twist Bioscience launched its HuTg model to expand antibody discovery services and complement existing in vivo platforms.Some support1 report
-
Twist Bioscience is based in South San Francisco.Some support2 reports
-
Twist Bioscience reported revenue growth compared to the industry average and its technology is noted for potentially replacing current computers.Some support2 reports
-
Twist Bioscience's RSI reading indicates heavy selling is exhausting itself, coinciding with analysts raising earnings estimates.Some support1 report
-
Twist Bioscience launched an Oncology DNA Comprehensive Genomic Profiling (CGP) Panel on August 19, 2025.Some support1 report
-
Twist Bioscience hosted a conference in New York City on September 3, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Twist Bioscience this week
News at the entities that move Twist Bioscience most-
SEC StructuralKahn Brothers Group Inc. purchased a stake in First National Bank Alaska, which operates in Alaska and files reports with the SEC.Moves Twist Bioscience
-
TD Cowen StructuralTD Cowen reaffirmed a buy rating while Cantor Fitzgerald downgraded monday.com Ltd. on October 6, 2026.Moves Twist Bioscience
-
Millennium Management TransactionalMillennium Management, specializing in Japanese government bonds, faced adverse strategy impacts due to yen rate volatility and filed regulatory records with the Monetary Authority of Singapore.Moves Twist Bioscience
-
Eli Lilly and Company OperationalMedicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.Moves Twist Bioscience
-
Ark Invest TransactionalArk Invest purchased over $25 million of Rocket Lab stock while the company continues to compete with SpaceX in launch services.Moves Twist Bioscience
-
LinkedIn Shared contextA dispute arose over false and defamatory advertisements involving a son's LinkedIn profile, operating under Pennsylvania state law.Moves Twist Bioscience
Connections
The 21 strongest of 58, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Emily Leproust Structural
Emily Leproust serves as the CEO of Twist Bioscience, managing company strategy and executing stock sales.
-
SEC Structural
Twist Bioscience is subject to formal disclosure and regulatory requirements imposed by the SEC.
-
Nasdaq Structural
Twist Bioscience is a company formally listed and trades on the Nasdaq stock exchange.
-
Paula Green Structural
Paula Green serves as the Senior Vice President of Twist Bioscience and trades its stock.
-
TD Cowen Structural
TD Cowen influences market perception of Twist Bioscience through financial ratings, target price adjustments, and buy recommendations.
-
Element Biosciences Operational
Element Biosciences and Twist Bioscience are collaborating on NGS tools, with Twist supplying exclusive library prep and enrichment kits.
-
Millennium Management Transactional
Millennium Management increased its holdings in Twist Bioscience.
-
Eli Lilly and Company Operational
Twist Bioscience and Eli Lilly have established a data services agreement to accelerate drug development.
Show all 21 connections
-
Ark Invest Transactional
Ark Invest executed a divestment by cutting its investment stake in Twist Bioscience as part of portfolio rebalancing.
-
Benzinga Operational
Twist Bioscience utilizes Benzinga's platform to disseminate company news and market updates.
-
Danaher Corporation Operational
The entities are identified as competitors operating within the life sciences sector.
-
Anthropic Mentioned together
The entities are co-mentioned as operating within the shared AI and biotech sectors and are subject to similar market dynamics.
-
Leerink partners Mentioned together
The relationship is characterized by shared market analyst coverage, specifically regarding price targets.
-
Twist Structural
Twist is identified as an insider who sold shares of Twist Bioscience stock.
-
ISI Mentioned together
Both ISI and Twist Bioscience are covered by the same analyst firm, leading to target price adjustments.
-
Barclays Mentioned together
Barclays issued a price target on Twist Bioscience.
-
MarketBeat Mentioned together
MarketBeat provides average rating and consensus target price information regarding Twist Bioscience.
-
Thermo Fisher Scientific Inc. Shared context
The two companies share the life sciences sector as their operational context.
-
LinkedIn Shared context
Twist Bioscience utilizes LinkedIn for professional networking and social media presence.
-
Corcept Therapeutics Mentioned together
Both companies are mentioned as holdings within various biotech investment funds.
-
SynBio Mentioned together
The evidence provided does not describe any relationship or interaction between Twist Bioscience and SynBio.
History
Events by the month they beganSeptember 2026
2 events- VUG concentrates on large-cap leaders like Nvidia. VUG holds large-cap leaders such as Microsoft. VUG holds established giants including Apple. IWO holds small-cap equities including Twist Bioscience.
- Twist Bioscience and BioLife Solutions are healthcare companies in the biotech sector listed on Nasdaq.
August 2026
2 eventsJuly 2026
2 eventsShow 1 earlier month
June 2026
15 events- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
- Twist Bioscience underperformed the market so far this year, based on data from August 4, 2025.
- Thermo Fisher Scientific and Twist Bioscience benefit from Trump-era tariffs while operating in the life sciences sector.
- Twist Bioscience filed disclosures with the SEC, listed its stock on Nasdaq, and received a rating upgrade from TD Cowen.
- Insider sold shares of Twist Bioscience stock on June 24, 2026.
- Life sciences companies Danaher Corporation and Twist Bioscience are facing headwinds due to exposure to China and academic spending.
- Twist Bioscience announced an accelerated Express turnaround time for all gene fragments.
- Twist Bioscience and LinkedIn were involved in an event on July 24, 2025.
- Conestoga Capital Advisors highlighted Twist Bioscience in its investor letter on July 28, 2025.
- Twist Bioscience launched its HuTg model to expand antibody discovery services and complement existing in vivo platforms.
- Twist Bioscience is based in South San Francisco.
- Twist Bioscience reported revenue growth compared to the industry average and its technology is noted for potentially replacing current computers.
- Twist Bioscience's RSI reading indicates heavy selling is exhausting itself, coinciding with analysts raising earnings estimates.
- Twist Bioscience launched an Oncology DNA Comprehensive Genomic Profiling (CGP) Panel on August 19, 2025.
- Twist Bioscience hosted a conference in New York City on September 3, 2025.